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1. Introduction  
The application of nucleic acid therapeutics sometimes requires the transfer of relatively 
large transgenes. For example, treatment of diseases such as hemophilia A, sickle cell 
disease, muscular dystrophy, or cystic fibrosis requires the transfer of coding sequences or 
complex regulatory elements, which can exceed 4.5 kilobases (kb). In general, transgenes are 
inserted into expression cassettes that can then be incorporated into either viral or nonviral 
vectors. The vector chosen depends not only on the therapeutic application but also on the 
size of the expression cassette. The size of the expression cassette depends on the size of the 
transgene and the requirement of specific regulatory elements necessary for appropriate 
transgene expression (for example, internal promoters, enhancers, insulators and other 
regulatory elements). Larger expression cassettes complicate gene therapy applications 
using viral vectors by (1) limiting the types of vectors available due to encapsidation 
limitations, (2) increasing the complexity of the transferred nucleic acid sequence, which, for 
example, can inadvertently introduce splice donor and acceptor sites, and (3) reducing the 
titer of viral vector that can be produced. Due to these hurdles, gene therapy strategies 
utilizing large expression cassettes are limited in vector design. One avenue of decreasing 
the size of transgenes is to genetically engineer minimal complementary DNA (cDNA) 
cassettes by eliminating regions that encode for non-functional aspects of the encoded 
protein. For example, the cDNA of human dystrophin, the missing functional gene in 
Duchenne’s Muscular Dystrophy, is approximately 11 kb. Due to its large size, a truncated 
functional version termed, mini-dystrophin, is utilized, thereby reducing the transgene size 
to 6 kb. A similar strategy has also been evaluated for the cDNA encoding factor VIII (FVIII), 
mutations of which cause hemophilia A. The transgene size has been reduced by 
eliminating an entire domain, thus reducing the transgene size by >2.5 kb. A second strategy 
that has been evaluated involves dividing a larger transgene into smaller sub-transgenes 
that can then be incorporated into separate vectors to be delivered simultaneously. Nonviral 
gene-delivery systems, on the other hand, are not as constrained by the size of the 
expression cassette. Despite this advantage, nonviral vectors are currently not widely used 
because of inefficient gene transfer. However, rapid progress is being made with 
transposons circumventing limited transfer by capitalizing on their ability to integrate 
within the genome. For example, the Sleeping Beauty transposon has been used to insert a 
number of large expression cassettes into the human genome, including the 6.5 kb ┚-globin 
expression cassette for the treatment of sickle cell disease. Therefore, these vectors hold 
much promise for gene therapy applications with large expression cassettes.  
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The gene therapy field has a reasonable level of understanding regarding how to transfer 
and manage some of the larger therapeutic payloads, and excellent progress has been 
achieved for some diseases. The transfer of the cDNA sequence encoding FVIII incorporates 
many of the strategies used to transfer large transgene sequences. Therefore, this chapter 
will focus on the methods developed to transfer the FVIII transgene. But the strategies 
described in this chapter can be, and have been, used to transfer similarly large nucleic acid 
sequences. For example, as shown in Figure I, several parameters have been manipulated to 
achieve safe gene transfer and high level expression. This chapter will describe (1) the 
various gene transfer platforms, such as viral and nonviral gene transfer systems that are 
available and their likely applications to the transfer of large sequences, (2) various methods 
and techniques for modifying large transgene sequences for greater expression, and (3) the 
introduction of various accessory sequences, such as internal promoters in viral vectors and 
the WPRE sequence, both of which may aid in RNA expression and export from the nucleus. 
Because the transfer of the FVIII cDNA sequence has incorporated many of these 
parameters, it is an excellent model for developing strategies requiring the transfer of large 
nucleic acid sequences. 
 
 
Fig. I. Schematic of a gene therapy expression cassette. 
The various parameters noted above can potentially be modified in order to achieve efficient 
gene transfer and expression of large nucleic acid sequences.  
2. Hemophilia A as a disease model for the transfer of large transgenes 
Hemophilia A is an X-linked bleeding disorder attributed to the loss of a functionally 
secreted FVIII protein. Approximately 1 in every 5,000 males have hemophilia A, equating 
to approximately 400,000 people across the globe (Doering and Spencer, 2009). The current 
treatment consists of repetitive prophylactic administration of recombinant or plasma 
concentrated FVIII as a means of protein replacement. However, this treatment doesn’t 
alleviate all the symptoms. Chronic joint pain can be experienced regardless of receiving 
optimal care. In addition, plasma concentrated FVIII historically has resulted in the 
transmission of blood borne pathogens (HIV, Hepatitis, etc.) to hemophilia patients and has 
thus, for the most part, been replaced with the administration of recombinant FVIII. 
Unfortunately, the recombinant form of FVIII is not available to a significant percentage 
(approximately 75%) of the individuals affected by the disease (Doering and Spencer, 2009). 
This is mainly due to the expense of treating hemophilia A, which on average can be 
$250,000 for recombinant FVIII product per year. Recombinant FVIII is costly because it is 
difficult to make resulting in periodic product shortages. It also has a low half-life in the 
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circulation requiring repetitive multi-weekly administration to achieve prophylaxis. Further 
complicating the current therapy, some individuals who receive this treatment develop an 
immunogenic response in the form of neutralizing antibodies against the administered 
FVIII. These inhibitors make managing a bleeding episode in these individuals extremely 
complicated. Therefore, new therapeutic approaches are being developed to treat 
hemophilia A. 
A monogenic disorder, such as hemophilia A, is a prime candidate for gene therapy for a 
number of reasons. First, the gene responsible for hemophilia A has been isolated and well 
characterized, which has led to useful preclinical mouse (Bi et al., 1995) and dog models 
(Kingdon & Hassell, 1981) as well as a newly described sheep model (Porada et al., 2010). 
Second, the delivery of FVIII is not restricted to certain cell types. In fact, any tissue with 
exposure to the vasculature is an appropriate cellular target in that FVIII only needs to be 
secreted into the bloodstream for effectiveness. This makes a gene therapy approach 
relatively straightforward and achievable. Third, the therapeutic window is large. Only a 
moderate increase in FVIII (2-5% of normal equating to 2-5ng/ml) is required to be 
therapeutically effective while levels as high as 150% of normal have not been associated 
with adverse effects such as thrombosis (VandenDriessche et al., 2001). As a result, a 
number of viral and nonviral delivery strategies have been postulated.  
2.1 Previous clinical trials  
Three clinical trials to date have been conducted. Each utilized the human cDNA FVIII 
sequence, but all three differed in the manner whereby the nucleic acid sequence was 
incorporated into the patients’ cells. The first trial by Roth et al. (2001) admitted six subjects 
with severe hemophilia A. Dermal fibroblasts were biopsied from each patient from the 
upper arm, expanded in tissue culture dishes in a laboratory incubator and electroporated 
(exposed to a voltage shock in order to perturb the cell membrane layer), resulting in the 
incorporation of the cDNA sequence into the fibroblast cells. After culturing, stably 
modified clones were selected and implanted into the omentum of each patient. Transient 
FVIII expression was observed within three of the patients for up to 6 months, with one 
patient expressing 4 percent of the normal amount of FVIII twelve weeks after implanting 
the genetically modified cells. However, the levels of FVIII diminished to less than 0.5% of 
normal a year later. The second trial included eleven subjects (Powell et al., 2003). Four 
doses (2.8 x 107, 9.2 x 107, 2.2 x 108, and 4.4 x 108 TU/kg) of a retroviral vector based on the 
Moloney murine leukemia virus (MoMLV) were administered via peripheral vein injection 
over three consecutive days. No adverse effects were observed throughout the 53 week 
study. Yet once again only a transient expression of FVIII was achieved. Eight of the patients 
demonstrated greater than 1% of normal FVIII levels on two or more occasions yet these 
levels were not sustained throughout the study and could be associated with the 
administration of exogenous recombinant FVIII. The final trial was performed by GenStar 
Therapeutics. One patient was injected intravenously with an adenovirus, which contained 
the full-length human FVIII cDNA. The patient acquired an immune reaction to the virus 
and the trial was abruptly closed (Berlfein, 2003).  
2.2 The FVIII transgene 
The three clinical trials for hemophilia A used the human FVIII cDNA sequence instead of 
the wild-type FVIII gene sequence. This is due to the large size of the wild-type FVIII gene. 
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In its entirety, the F8 gene is approximately 180 kilobases (kb) long and is comprised of 26 
exons. It is transcribed into a 9010 base pair (bp) transcript with a short 5’ untranslated 
region (150bp) and a large 3’ untranslated region (1806bp), and a 7056 bp open reading 
frame the encodes the FVIII protein. The open reading frame of the FVIII transcript is 
translated into a protein containing a short 19 amino acid signal peptide, which is necessary 
for cellular excretion, and the 2332 amino acid protein with a distinct domain structure 
denoted A1-A2-B-A3-C1-C2. The B domain, comprising a total of 907 amino acids, is not 
found within the functional protein. Instead it contains sequence motifs recognized by both 
intracellular and extracellular proteases (Bowen, 2002). For example, FVIII is cleaved 
intracellularly after Golgi processing at two separate arginine residues within the B domain 
yielding a FVIII heterodimer composed of a heavy chain (A1 and A2 domains, as well as a 
shortened B domain) and a light chain (A3, C1 and C2 domains) held together by a calcium 
ion bridge. Further cleavage occurs extracellularly in which thrombin cleavage releases the 
remainder of the B domain resulting in FVIII activation (Lenting et al., 1998).  
Large transgenes, such as the FVIII transgene, complicate gene therapy applications using 
viral vectors by (1) limiting the types of vectors available due to encapsidation limitations 
(see Table I) and (2) reducing the titer of viral vector that can be produced (Kumar et al., 
2001; Radcliffe et al., 2008; Yacoub et al., 2007). The different human cDNA transgene 
lengths chosen for the clinical trials are a reflection of these limitations. The GenStar 
Therapeutics trial, unlike the other two trials, utilized an adenovirus which has fewer 
encapsidation constraints than other viral vectors available for gene transfer. As a result, it 
was the only trial to utilize the full-length cDNA 7kb sequence. The Powell clinical trial, on 
the other hand utilized a retrovirus. Although retroviruses have the capability of 
encapsulating 7kb of exogenous DNA, incorporating a 7kb transgene into a retrovirus 
results in diminished viral titer making it difficult to achieve a high enough number of viral 
particles to be effective. Reducing the size of the insert, however, can increase viral titer 
(Yacoub et al., 2007). For this reason, many groups are using viral vectors and have reduced 
the size of the cDNA to approximately 4.5 kb. This can be accomplished by removing 
sequence that encodes the B domain, which has been found to be dispensable for the 
coagulation activity of FVIII (Toole et al., 1986). 
 
 
* A low frequency (up to 10%) of wild-type adeno-associated vectors has been found to integrate within 
chromosome 19 (Kotin et al., 1990). 
Table I. Properties of major gene transfer methods used in gene therapy. 
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As demonstrated above, the complications associated with the large FVIII transgene has led 
researchers to find innovative ways to apply gene therapy techniques to the transfer of the 
FVIII transgene. The following sections will discuss the methods that have been proposed 
for the pre-clinical testing of gene transfer technologies for FVIII. These methods will be 
outlined in reference to which vector is being used, since each vector is accompanied with 
its own set of limitations (Table 1). Both viral and nonviral vectors will be discussed, 
highlighting the strategies utilized to overcome the limitations experienced due to the use of 
a large transgene.   
3. Viral vectors 
Within the field of gene therapy, many viral vectors have been considered for the 
modification of cells, including both nonintegrating and integrating vectors. Nonintegrating 
vectors, such as the adenoviral and adeno-associated viral vectors, persist within cells 
extrachromosomally. As nonintegrating viruses, there is the risk that the vector genome will 
be lost, particularly if the modified cell divides. Yet, adenoviral vectors and adeno-
associated viral vectors are appealing in that they efficiently transduce both dividing and 
non-dividing cells. If non-dividing cells are targeted then it is possible that long term 
expression can be achieved with these vectors. This quality allows these vectors to be able to 
target the most likely primary endogenous producers of FVIII, the terminally differentiated 
non-dividing hepatocytes.  
Since adenoviral vectors are not constrained by insert size, they were among the first to be 
used as therapeutic gene transfer vectors within clinical trials. However as mentioned 
previously in reference to the GenStar FVIII clinical trial, systemic administration of 
adenoviral vectors resulted in acute toxicity (as evidenced by elevation of liver enzymes) 
as a result of the induction of pro-inflammatory cytokines and chemokines directed 
against the viral capsid proteins (Aruda, 2006; Brunetti-Pierri et al., 2004; Schnell et al., 
2001; Muruve, et al., 1999; Yang et al., 1994). This toxicity can be circumvented if 
adenoviral vectors are administered neonatally, capitalizing on the immaturity of the 
immune system during early development. Therefore, adenoviral vectors are now being 
considered for use within neonates to induce FVIII tolerance. This was recently achieved 
within hemophilia A mice after intravenous injection of 5 x 1012 vector particles/kg 
administered at three days of age (Hu et al., 2011). FVIII levels peaked at ~650% of normal 
on day six, but declined with animal growth as a result of episomal vector loss. Therefore, 
the single administration of adenoviral vectors within neonates was not able to achieve 
sustained therapeutic levels of FVIII. However, tolerance to the transgene and viral capsid 
proteins was achieved as noted by the lack of adverse effects after subsequent vector 
administration (Hu, 2011). It is worthwhile to note that this therapy could also be 
beneficial, in the absence of subsequent vector administration, to prevent the 
development of inhibitors to FVIII which currently complicates protein replacement 
therapy. In the context of gene therapy for hemophilia A, adenoviral vectors are only 
being considered for the induction of FVIII tolerance within neonates due to the extensive 
inflammatory response observed after presentation of the vector to the systemic 
circulation. This is unfortunate since the vector can withstand the large size of the FVIII 
transgene as well as any number of regulatory elements used within the field for 
expression enhancement or safety. Adeno-associated viral vectors, on the other hand, are 
being extensively evaluated for use within gene therapy. 
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3.1 Gene transfer of FVIII with adeno-associated viral vectors 
The adeno-associated viruses are relatively small viruses, composed of a linear single-
stranded DNA genome of approximately 4.6 kb. As of 2009, twelve different serotypes have 
been isolated from both human and non-human primates (a number which is expected to 
increase), all of which vary in transduction efficiency and tissue tropism (Youjin and Jun, 
2009). Serotype 2 (AAV-2) was the first adeno-associated virus to be sequenced and cloned, 
and was therefore the first serotype to be used within gene transfer studies (Hermonat and 
Muzyczka, 1984; Laughlin et al., 1983; Samulski et al, 1982). Wild-type AAV-2 was found to 
encode two large open reading frames, composed of the replication (Rep78, Rep68, Rep52, 
and Rep40) and capsid genes (VP1, VP2, and VP3). To accommodate transgenes, these genes 
were removed leaving behind the inverted terminal repeats required for replication and 
packaging into a viron (Youjin and Jun, 2009). AAV-2 and other AAV serotypes have the 
ability to efficiently transduce both non-dividing and dividing cells (Hallek et al., 1998). This 
quality makes modifying hepatocytes in vivo possible, making them a potentially ideal 
vector for FVIII delivery. In this aspect, hepatocytes have been modified by a number of 
adeno-associated viral serotypes. For example, AAV-2, after intraportal administration, 
transferred a canine B domain deleted version of FVIII to liver cells, which resulted in 
partial phenotypic correction of hemophilia A mice. Although FVIII activity initially peaked 
to 8% of normal, expression was not sustained, declining to 2% nine months after injection 
(Sarkar et al., 2003). These findings, although confirmed independently by Jiang et al. (2003), 
are contradictory to similar preclinical and clinical studies for hemophilia B in which 
therapeutically effective levels of FIX are sustained over time (Manno et al., 2005 and 
Schuettrumpt et al., 2005). This is because FIX is a significantly smaller transgene than FVIII 
with a cDNA of 2.8 kb. This smaller sequence allows for the inclusion of larger regulatory 
elements (such as liver specific promoters and enhancers) within the adeno-associated viral 
vector that are not able to be incorporated after the inclusion of the FVIII cDNA sequence. 
Within the Jiang (2003) and Sarkar (2003) reports, a minipromoter was all that could be 
incorporated into the AAV-2 vector to promote FVIII expression. Therefore, it was 
concluded that regulatory elements, that were unable to be included in the AAV-2 vector 
(due to insert size restraints associated with adeno-associated viral vectors), were required 
to enhance FVIII expression. A follow up study evaluated additional adeno-associated viral 
serotypes (AAV-5, AAV-7, and AAV-8) to determine if other serotypes were more efficient 
at transducing hepatocytes than AAV-2. For the inefficient transfer of large transgenes, it 
was hypothesized that by increasing hepatocyte transduction, limited expression could be 
overcome without the inclusion of regulatory expression-enhacement elements. They found 
that AAV-8 was superior to other serotypes regardless of route of administration 
(intraportally or intravenously) producing near normal physiological levels of FVIII (0.58 + 
0.2 IU/mL) six months post administration at a vector dose of 1 x 1011 vector copies / mouse 
(Sarkar et al., 2004). A similar comparison was performed by Jiang et al. (2006), comparing 
four serotypes (AAV-2, AAV-5, AAV-6, and AAV-8), within both mice and dogs. Within 
mice, transduction efficiency was found to be least with AAV-5 and greatest with AAV-8. 
However for dogs, no substantial difference was observed among the serotypes. 
Remarkably though, FVIII expression was sustained in some dogs (2 to 5% of normal) for up 
to three years, resulting in decreased occurrences of spontaneous bleeds (Jiang et al., 2006). 
This was a significant contribution to the field being the first multiyear report of therapeutic 
efficacy and safety within dogs. Albeit, high vector doses of 6 x 1012 and 2.7 x 1013 vector 
genomes/kilogram were required to yield these subtherapeutic levels of FVIII.   
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Despite the phenotypic improvements noted above, the inclusion of regulatory elements to 
the vector for enhancing the expression of FVIII would have been the simplest way to 
address the limited hepatocyte transduction that was seen with AAV-2. Yet since adeno-
associated viral vectors are restricted in their genetic carrying capacity, other avenues had to 
be evaluated to overcome this limitation. Some reports show packaging of genomes greater 
than 5kb within adeno-associated vectors (Alloca et al., 2008 and Grieger and Samulski, 
2005). For example, it is reported that an AAV-8 viral vector was produced containing the B 
domain deleted human FVIII transgene as well as a full length promoter and enhancer, 
totaling 5.75 kb (Lu, 2008). However, extensive examination within this report as well as by 
Wu (2010) clearly showed that inserts ranging from 4.7 kb to 8.7 kb result in heterogenous 
virons of varying genome lengths, typically containing truncations at the 5’ end. Thus, 
increasing the size of the adeno-associated vector genome leads to the formation of defective 
viral particles encapsulating incomplete transgene sequences (Dong et al., 1996).  
For these reasons, several groups are attempting to overcome the packaging limitation 
with the use of two different vectors, one for the heavy chain and one for the light chain of 
FVIII. This strategy resulted from the demonstration of secretable biologically active FVIII 
following co-transfection within Chinese hamster ovary cells of two plasmids separating 
the heavy and light chains (Burke et al, 1986 and Yonemura et al., 1993). Within these cells 
the two polypeptide chains were able to reconstitute a functional FVIII heterodimer that 
was secreted into the cellular media. Although this strategy may be unique to hemophilia 
A gene therapy applications due to the structural properties of the protein, similar 
strategies could be implemented in other large transgenes. This strategy was first 
performed in C57BL/6 mice by intraportal administration (Burton et al., 1999). These mice 
were chosen since this strain does not elicit an immune response to the FVIII transgene, 
allowing expression to be measured without any contraindications. As a result, greater 
than physiological levels of FVIII were produced. These results were then extended into 
the hemophilia A mouse model where therapeutic levels of FVIII were achieved in a dose-
dependent manner. High levels of transduction were noted with twelve percent of 
hepatocytes being modified with both vectors. Complicating the issue, a chain imbalance 
was noted with a 25 to 100 fold excess of light chain. This was found to be due to 
inefficient translational or posttranslational processing that could not be circumvented by 
changing the administration ratio of heavy to light chain vectors (Scallan et al., 2003). 
When extended to the hemophilia A dog model, only partial phenotypic correction was 
achieved, irrespective of adeno-associated serotype used. Although only modest levels of 
FVIII were observed in the dogs (ranging from 1 to 8% of normal), these levels were found 
to be sustained for at least two years (Sarkar et al., 2006). 
Another strategy used to overcome the inability of adeno-associated vectors to deliver large 
genes is trans-splicing. Trans-splicing attempts to repair the truncated FVIII mRNA in vivo 
by delivering the remaining downstream pre-mRNA. Within this strategy, a pre-trans-
splicing molecule is delivered by an adeno-associated vector in which complementary 
mRNA sequences are located at the 5’ end of the molecule designed to be spliced with the 
preexisting truncated FVIII mRNA due to a strong splice site at the 3’ end. In this way, a 
shortened version of the transgene can be delivered in vivo to restore the disease phenotype. 
This method was performed in hemophilia A mice (Chao et al., 2003). Hemophilia A mice 
were created by inserting a neomycin resistance gene into the sixteenth exon of FVIII (Bi et 
al., 1995). As a result truncated FVIII mRNA is still expressed within these mice. By 
delivering a pre-trans-splicing molecule containing complementary sequence to intron 15, a 
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functional FVIII pre-mRNA was spliced together in vivo resulting in phenotypic correction 
within eight of the ten injected mice.  
Despite these efforts the fact remains that nonintegrating adeno-associated viral vectors are 
unable to stably transduce cells. Therefore, many groups are focusing on the use of 
integrating viral vectors such as gamma-retroviral and lentiviral vectors. Lentiviral vectors, 
such as HIV and SIV, have been analyzed for their use within gene therapy since 1996 in 
which Naldini and colleagues revealed the ability of these vectors to overcome the need for 
cell division during transduction. Being able to transduce both dividing and non-dividing 
cells gives lentiviral vectors the same advantage as adeno-associated viral vectors. For this 
reason, lentiviral vectors are likely to make up a second generation of therapeutic vectors to 
be tested in clinical trials. 
3.2 Gene transfer of FVIII with lentiviral vectors 
Stable integration of a transgene can be achieved with integrating viruses, such as gamma-
retroviral and lentiviral vectors. However, genomic integration of a viral vector has 
concerned the gene therapy community because of the possibility of cellular transformation 
due to integration of the transgene near an oncogene. This process has been termed 
insertional mutagenesis, and can cause misregulation of oncogene expression, which could 
subsequently lead to malignancy. Historically, insertional mutagenesis has been debatable 
due to the lack of data confirming its occurrence. However, recent data has confirmed the 
possibility of insertional mutagenesis due to retroviruses. First, retroviruses have been 
found to insert into the genome near promoters of transcriptionally active genes, setting the 
stage for the disrupted regulation of downstream genes (Wu et al., 2003). Second, direct 
proof of insertional mutagenesis has been documented in human gene therapy clinical trials 
for the treatment of severe combined immune deficiency syndrome that used gamma-based 
retroviruses (Hacein-Bey-Abina et al., 2003). In the initial clinical trials, of the 20 treated 
children, 5 have developed a T-cell leukemia-like disorder. The cause of the leukemia has 
been found to be due to integration of the gamma-retrovirus upstream of the oncogene, 
LMO2. Integration at this site disrupted the regulation of the oncongene increasing the 
expression of LMO2. The confirmation of insertional mutagenesis with gamma-retroviral 
vectors halted their use for clinical development for hemophilia. However, no direct 
evidence for insertional mutagenesis has been documented for recombinant lentiviral-based 
retroviruses. Instead, lentiviral vectors have been promising vectors for the delivery of the 
FVIII transgene because, like adeno-associated viral vectors, they are able to transduce both 
dividing and non-dividing cells, (Naldini et al., 1996) but unlike adeno-associated viral 
vectors are not as constrained by the size of the transgene. For these reasons, lentiviral 
vectors are ideal for gene therapy applications aimed for the treatment of hemophilia A. 
The first lentiviral vectors contained all of the viral genes except for the envelope gene 
(Naldini et al., 1996). Since then numerous safety measures have been taken to ensure the 
safety of the virus in the unlikely event of generating a replication competent lentivirus. 
Second generation HIV-based vectors removed 5 of the 9 viral genes, eliminating accessory 
genes (Quinonez & Sutton 2002). As an added precaution second generation lentiviral 
vectors have been designed as replication incompetent self-inactivating (SIN) vectors. This 
has been accomplished by removing 133 bps from the 3’ long terminal repeat (LTR). LTRs 
flank viral DNA at both the 3’ and 5’ ends and are involved in the integration process (for 
further discussion refer to Sinn et al., 2005). During the process of integration, the 3’LTR is 
copied and becomes the 5’LTR in the integrated sequence, which inactivates the integrated 
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5’LTR. Further safety measures resulted in the third generation lentiviral vectors, in which 2 
more viral genes (the tat and the rev genes) were eliminated. To date these third generation 
lentiviral vectors have been used for gene therapy applications without any adverse 
complications (Cartier et al., 2010). 
Lentiviral vectors have a carrying capacity of approximately 7kb exogenous DNA. Although 
still constrained by encapsidation limitations, lentiviruses can be used to shuttle a number of 
transgenes that are restricted within the adeno-associated viral vector. However, as the 
insert size increases the viral particles produced (as measured by viral titer) can decrease 
(Yacoub et al., 2007). This phenomenon has been observed by several laboratories that use 
the 4.5 kb B domain deleted FVIII transgene. Because of this limitation, focus has been on 
reducing the insert size within the lentiviral vector. One component of the viral vector, 
which can be considered to be removed for this purpose, is the woodchuck post-
transcriptional regulatory (WPRE) sequence (~ 600bp).  
Zufferey et al. (1999) incorporated a WPRE sequence at the 3’ end of the transgene and 
demonstrated a 2- to 5- fold increase in expression. The enhancement in expression appears 
to be due to increased export of unspliced mRNA (Zuffery et al., 1999). Viral vectors used 
for the purpose of gene therapy utilize cDNA sequences, which are not spliced due to vector 
size constraints and therefore experience limited export of the mRNA. This limited export of 
unspliced transgene mRNA compounds the low level expression obstacle experienced 
historically. Thus, the inclusion of either splice donor and acceptor sites or a WPRE 
sequence appears to be ideal. As a result, the WPRE has routinely been incorporated into 
viral vectors. However, a recent report showed that the function of WPRE as a transgene 
expression enhancer may not be as advantageous as previously determined. The 
enhancement of transgene expression due to a WPRE sequence was found to be dependent 
on the promoter and cell line used. In general, the WPRE sequence enhances transgene 
expression, but in some instances no increase and even a decrease in transgene expression is 
observed. It was concluded that the function of the WPRE is more complex than originally 
assumed and should be evaluated in conjunction with every transgene (Klein et al., 2006). 
For this reason, the WPRE was evaluated in the context of an optimized high-expressing 
FVIII transgene and found to be negligible in regards to transgene expression as assessed by 
both transcript number and FVIII activity (Johnston et al., 2010). The effects were also 
negligible in regards to viral transduction. For these reasons, the WPRE can be considered 
for removal from some lentiviral backbones in order to reduce the insert size. 
To further overcome issues of FVIII expression several bioengineered FVIII constructs have 
been proposed, many of which target the efficient transport of FVIII from the endoplasmic 
reticulum to the golgi (Dorner et al., 1987). For example, removal of the B domain, besides 
shortening transgene length, was also found to be beneficial by increasing mRNA 
production 20-fold (Meulien et al., 1988). However, efficient secretion of FVIII requires N-
linked glycosyl residues found within the B domain. Therefore, retaining these sites within a 
truncated B domain may be a preferred shortened FVIII construct (Miao et al., 2004). In 
addition to the above engineering schemes, amino acid substitutions within the A1 domain 
were incorporated in order to diminish binding to an ER resident protein chaperone, which 
resulted in enhanced FVIII production (Marquette et al., 1995 and Swaroop et al., 1997). A B 
domain deleted porcine FVIII transgene was also evaluated revealing a 10 – 14 fold increase 
in expression compared to a human FVIII transgene (Doering et al., 2002). Its subsequent 
transfer within hemophilia A mice resulted in high-level FVIII expression that could be 
sustained even after low-toxicity pretransplantation conditioning (Ide et al., 2007). Together, 
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these studies demonstrated the ability of a high-expressing porcine FVIII construct to 
function in vivo. A comparison of these transgenes revealed the superiority of the porcine B-
domain-deleted FVIII with a 36 to 225-fold increase in FVIII expression (Dooriss et al., 2009). 
These findings suggested that the current low-level expression obstacle could be eliminated 
if the sequences that are responsible for the enhanced secretion of porcine FVIII were 
identified. To accomplish this, human/porcine FVIII chimeras were constructed that 
revealed sequences within the A1 and A3 domains to be responsible for enhanced secretion 
of porcine FVIII (Gangadharan et al., 2006).  The result was a hybrid human/porcine 
construct comprising ~ 90% human FVIII, designated HPFVIII, which has been shown to 
maintain the high-expression characteristics of the porcine sequence. This optimized 
HPFVIII transgene has recently been used to treat hemophilia A mice, which resulted in 
therapeutic levels of FVIII being observed after modifying hematopoietic stem cells (HSC) ex 
vivo with lentiviral vector (Doering et al., 2009). A codon optimized FVIII cDNA also has 
been reported and shown to enhance expression after in vivo administration to neonatal 
hemophilia A mice (Ward et al., 2011).  
Reduction in transgene titers due to issues associated with transgene size can be overcome 
by targeting various cell populations ex vivo then expanding the genetically modified cells. 
Therefore, despite diminished titer production, preclinical progress has been made with 
lentiviral vectors encoding the 4.5kb B domain deleted FVIII transgene. And, by targeting 
specific cells, viral transduction can be optimized and enhanced, which further overcomes 
the reduction in titer due to transgene size. In addition, ex vivo modification of cells is 
considered safer than the in vivo delivery of recombinant virus since it eliminates the 
possible transmission to germline cells, as well as avoiding any systemic toxicity that can 
result due to direct presentation of the vector particle (Van Damme et al., 2004). Ex vivo 
modification also eliminates the issue of modifying antigen-presenting cells, possibly 
eliminating the development of an immune response to the transgene. 
Ex vivo gene therapy for hemophilia A has been analyzed within a broad range of cell types 
(Viiala et al., 2009). Cellular alternatives considered include embryonic stem (ES) cells, bone 
marrow derived mesenchymal cells, blood outgrowth endothelial cells (BOECs), and HSCs 
(as discussed previously). Stem cells are a reasonable alternative in that they have unlimited 
replicative potential and contain the ability to differentiate into a wide range of cells. 
However, the initial use of stem cells within the field of gene therapy resulted in low 
expression levels. This was thought to either be due to gene inactivation as a result of 
extensive differentiation (McIvor, 1987) or an inability to effectively transduce stem cells. 
Regardless, promising results were published utilizing an inducible system for FVIII within 
ES cells. However, both ethical and safety concerns have inhibited the continuation of these 
studies (Kasuda et al., 2008). This is due to the controversy surrounding the generation of ES 
cells from human embryos, as well as the formation of teratomas which arose from 
undifferentiated ES cells used for insulin production (Fujikawa et al., 2005). Fortunately, 
induced pluripotent stem cells (iPS) appear to be comparable to ES cells and have thus been 
considered to treat monogenic disorders in order to alleviate the ethical concerns 
surrounding stem cell usage. iPS cells are derived from adult somatic cells which have been 
reprogrammed to have stem cell characteristics. Significant progress has been made utilizing 
iPS cell-based therapy for murine hemophilia A (Xu et al., 2009). However, these methods 
are fairly new and still do not address the potential formation of teratomas. Therefore, many 
obstacles need to be addressed before this therapy can reach the clinics (for further 
discussion refer to Liras, 2011). Another cell type, bone marrow derived mesenchymal cells, 
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initially yielded therapeutic levels of FVIII from transduced human mesenchymal cells 
within immunodeficient mice. Yet FVIII plasma levels deteriorated gradually in spite of the 
persistence of gene modified cells, suggesting transcriptional repression within this cell type 
(Van Damme et al., 2004). Human BOECs can be isolated from the peripheral blood of 
healthy donors and were considered as FVIII gene transfer targets because they express von 
Willebrand factor (vWF). vWF binds with high affinity to FVIII in the circulation and 
protects FVIII from degradation and uptake by antigen presenting cells (possibly 
eliminating the development of an immune response to the transgene) (Dasgupta et al., 
2007). Therefore, it was hypothesized that modifying these cells to also express FVIII would 
result in the secretion of FVIII complexed to vWF, which would result in an increased half-
life of FVIII, secreted at sites of injury. After transduction, BOECs expressed high levels of 
FVIII measured at 1.6 pmol/million cells/24hrs, which lasted for over thirty days in culture. 
FVIII was found to be stored within the same vesicles as VWF within the BOECs but was 
not found to be released upon agonist stimulation, unlike vWF. Instead, FVIII appeared to 
be released in a constitutive manner (van den Biggelaar et al., 2009).  When BOECs were 
implanted into immunocompetent hemophilic mice, FVIII levels were within the therapeutic 
range for a total of 27 weeks. Afterwards, the levels declined to baseline due to loss of the 
implanted BOECs (Matsui, et al., 2007). Although a benefit for FVIII secretion with vWF was 
not directly tested, the proof of concept was shown for the expression of FVIII from BOECs. 
Another cell target, which has been considered, is skeletal muscle cells. Skeletal muscles 
cells are an ideal target for in vivo gene transfer in that skeletal muscle cells are terminally 
differentiated and provide a consistent source of FVIII persisting throughout the lifetime of 
an individual. For these reasons, Jeon et al. (2010) injected 107 lentiviral particles 
intramuscularly into the thigh of rats and found plasma FVIII levels to increase slightly 
above that of control mice for up to 4 weeks before deteriorating. Despite the need for follow 
up studies in order to achieve therapeutic levels of FVIII with this strategy, the results 
suggested that the in vivo administration of a lentivirus targeted at skeletal muscle cells may 
be an effective strategy for the treatment of hemophilia A. Most in vivo strategies, however, 
are aimed at targeting hepatocytes, the endogenous producer of FVIII. Lentivirus is 
administered via either the portal vein or intravenously. Unfortunately this strategy in the 
case of FVIII (a protein with extensive immunogenicity properties), results in the 
presentation of anti-FVIII antibodies due to the possible transduction of antigen presenting 
cells. To overcome this, a miRNA sequence was incorporated downstream of the WPRE 
sequence which would prevent expression within hematopoietic cells (including cells which 
make up the immune system). This method was found to be very effective in eliminating a 
FIX immune response (Brown et al., 2007), but alone was unable to do so with FVIII. Instead 
the FVIII-miRNA lentivirus had to be pseudotyped with the baculovirus envelope 
glycoprotein GP64, which has been shown to restrict transduction away from hematopoietic 
stem cells (Schauber et al., 2004). Combined, the miRNA incorporation and the GP64 
pseudotyping were able to restrict FVIII expression to the liver, eliminating the presence of 
inhibitors, while resulting in about 9% of normal levels of FVIII (0.1U/mL), which was 
sustained in mice for a total of 60 weeks (Matsui, 2010). This study was significant in that it 
modified the current in vivo lentiviral gene transfer of FVIII making it safer by restricting 
expression within the liver.  
In contrast to focusing on transferring the missing or malfunctioning gene, constructs that 
encode proteins that can bypass the missing protein can be used to overcome the difficulties 
associated with the size of the transgene. In the case of hemophilia A, a smaller gene such as 
FVII can be used to bypass the need for FVIII. FVII is an extrinsic pathway coagulation 
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factor that along with thromboplastin initiates the blood coagulation proteolytic cleavage 
cascade and has been shown in a recombinant form to be an alternative treatment for 
hemophilia A (Jurlander et al., 2001). For these reasons, Ohmori et al. (2008) transduced 
HSCs ex vivo with a simian immunodeficiency virus (SIV)-based lentiviral vector encoding 
an activated form of FVII expressed from a platelet specific promoter (the GPIb┙ promoter). 
As a result, FVII was found to localize to the cell surface following platelet activation within 
transplanted FVIII-deficient mice. Due to species-specific interactions, the murine TF was 
unable to interact with the human form of FVII resulting in unimproved hemophilia 
conditions within the FVIII-deficient mice. However, when a murine FVII was incorporated 
into the SIV-based lentiviral vector, the clot time and rate of clot formation were 
significantly reduced, decreasing the mortality rate after tail clipping (Ohmori et al., 2008). 
In addition, FVII was recently incorporated into an adeno-associated vector (AAV-8) being 
able to overcome the encapsidation limitations of the vector due to the shorter size of FVII. 
Yet it was shown that within hemophilic dogs, large doses of vector were required to be 
efficacious (Margaritis et al., 2009). Therefore, a bioengineered FVII variant with enhanced 
intrinsic activity was recently utilized in order to reduce the dose of in vivo administered 
vector. However, adverse thrombotic effects were observed in treated mice, which limits 
enthusiasm for this therapy. (Margaritis et al., 2011).  
4. Nonviral vectors 
Unlike viral vectors, nonviral vectors themselves do not risk evoking an immunological 
response, are less expensive to produce, and are less limited by the size of the transgene. As 
a result, naked DNA gene transfer was among the first methods to be utilized in a clinical 
trial for hemophilia A (Roth et al., 2001). However, this strategy results in transient gene 
expression because of limited uptake by target cells and further limited integration into the 
genome of these cells (a process that unless further manipulated occurs only randomly 
through nonhomologous recombination) (Essner et al., 2005). This issue can be overcome by 
promoting stable integration into the cell’s genome with the use of a transposable element. 
Transposable elements, although mostly inactive, are found to be littered throughout the 
human genome (Deininger and Batzer, 2002). In an active form, transposable elements 
(transposons) have the ability to jump from one location in the genome to another by a “cut-
and paste” method through the enzyme transposase, which is encoded within the element. 
In order for a transposon to be utilized as a gene transfer vehicle, two components must be 
delivered to the target cell, (1) the transgene flanked by inverted repeat/direct repeat 
elements that are recognized for integration, and (2) a transposase which can be encoded 
within the same plasmid or within a second plasmid. These plasmids can be taken up into 
cells after being complexed to a cationic polymer such as polyethylenimine (PEI).  
Although transposons can carry an expansive amount of DNA, transposons are still 
somewhat limited by insert size. Integration efficiency has been shown to decrease with the 
size of the transgene (Essner et al., 2005). This is due to both the difficulties in delivering 
plasmids containing larger inserts as well as the limitations of the transposase. For example, 
the transposase enzyme associated with the Sleeping Beauty transposon, the most notable 
nonviral gene-delivery system currently used, is only able to transpose up to 10kb.  
4.1 Gene transfer of FVIII with a transposon 
Transposons have been utilized as a nonviral vector for gene therapy of hemophilia A by a 
number of groups. The Sleeping Beauty transposon system was engineered from an inactive 
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Tc1-like transposable element found within fish (Ivics et al., 1997). It has since been used to 
insert a number of large expression cassettes into the human genome, including the 6.5 kb ┙-
globin expression cassette for the treatment of sickle cell disease (Zhu et. al, 2007). For 
hemophilia A, the Sleeping Beauty transposon/transposase system was utilized by Liu et al. 
(2006) to express the human B domain deleted FVIII cDNA within endothelial cells. FVIII 
levels remained at ~12% of normal after intravenous plasmid injection through the temporal 
vein of neonatal hemophilia A mice. However, the presence of inhibitors to FVIII resulted in 
only partial phenotypic correction (Liu et al., 2006). In order to circumvent the presence of 
inhibitors, the Largaespada group tolerized neonatal, one day old, hemophilia A mice to 
FVIII with a facial vein injection of 0.1U/g of recombinant human FVIII. Eight to twelve 
weeks later, two high pressure tail vein injections of a Sleeping Beauty transposon were 
administered. As a result, 16% of normal FVIII levels were seen within these mice at eighty-
four days after plasmid injection, which was found to be sustained for 6 months. No 
inhibitors were detected and an improvement in clotting function was noted (Ohlfest et al., 
2005).  
The high-pressure method of delivery is accomplished by injecting a high volume into the 
systemic circulation (termed hydrodynamic injections). Within the mouse, this results in 
DNA uptake followed by expression within the liver. Designed to overcome the difficulties 
of delivering DNA to the nucleus of a cell, high-volume high-pressure injection is not yet 
applicable for people (Essner et al., 2005). Therefore, other methods of transposon delivery 
are being explored. One method that is being studied is the cell specific delivery of a 
transposon by encapsulation within a nanocapsule. A recent report by Kren et al. (2009) 
utilized a novel dispersion atomization technique to encapsulate the Sleeping Beauty 
transposon system. The engineered nanocapsule was targeted to liver sinusoidal endothelial 
cells (LSECs) by coating the capsule with an endogenous ligand for the hyaluronan receptor 
found on LSECs. Inside the nanocapsule a single plasmid was encapsulated containing both 
a cis-acting transposase as well as the B domain deleted canine FVIII transgene. Eight-week 
old hemophilia A mice were injected with 25µg of nanocapsule via tail vein injection. FVIII 
levels were measurable for a total of 11 months.  
The size limitations of transposons have recently been expanded. Recently, a number of 
improvements have been made resulting in a hyperactive transposase, which appears to be 
able to improve transpositional efficiency to transgenes greater than 10kb (Zayed et al., 
2004). These improvements will be useful for the transfer of large transgenes and expression 
cassettes within gene therapy.  
5. Conclusion  
Gene delivery systems are available for the routine delivery of nucleic acid sequences below 
approximately 3 kb. As the transgene size increases beyond this, the complexity of 
transferring the larger sequences increases as well. Many systems have been tested for 
transferring large transgene sequences and some have shown reasonable promise. In 
general, viral vectors efficiently transfer these larger sequences, but several hurdles hamper 
gene transfer, namely: (1) limitations in the size of genetic material that can be packaged in a 
viral vector, (2) the inadvertent introduction of splice donor and acceptor sites, and (3) 
reduction of viral titer. Therefore, although efficient gene transfer systems are available, and 
clinical trials have confirmed the usefulness of some systems, there is still a need for 
improved gene transfer systems for large payloads. Even though optimal systems are not 
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available, several strategies can be used to transfer large nucleic acid sequences. These 
strategies revolve around manipulating the various components of the expression cassette, 
specifically (1) introducing the sequence into multiple viral or nonviral gene transfer system 
to determine the best for the specific transgene (2) modifying the transgene sequence, for 
example by deleting coding sequences that may not be important to the function of the 
expressed protein, and (3) removing various accessory sequences that may not be necessary, 
or incorporating accessory sequences with optimal expression properties, such as stronger 
promoter elements. The transfer of FVIII is an excellent example of how some of these 
limitations were overcome. The transgene that encodes FVIII is very large (7kb). Within the 
context of expressing FVIII for the treatment of hemophilia A, both viral and nonviral 
vectors have been tested. Viral vectors were first used to provide proof-of-principle that 
hemophilia A could be treated by gene therapy (VandenDriessche et al., 1999). However, the 
efficiency of FVIII gene transfer has hampered the progress of developing a gene therapy 
treatment for hemophilia A. Since then, the FVIII transgene has been truncated from 7kb to 
4.5kb by removing the B domain, a non-functional region of the protein. A number of 
groups have focused on shortening FVIII even further by dividing FVIII into two smaller 
sub-transgenes, one encoding the heavy chain and another encoding the light chain. Besides 
focusing on the FVIII transgene itself, other components of the expression cassette have also 
been evaluated, such as removal of the WPRE sequence and testing of various promoters.  
Despite these innovative methods, viral vector design is limited, prohibiting the addition of 
other regulatory or safety sequences. Nonviral vector systems, on the other hand, are not as 
constrained by the size of the expression cassette. However, these vectors have been 
historically associated with inefficient and unstable gene transfer. The Sleeping Beauty 
transposon may be able to circumvent this disadvantage by stably integrating the transgene 
into the target cell’s genome. Overall, tremendous progress has been made to overcome the 
limitations associated with large expression cassettes. We now have a reasonable level of 
understanding, within the gene therapy field, of the limitations of the various gene transfer 
systems. The ability to transfer larger and more complex genetic expression cassettes will 
allow for more sophisticated approaches for targeting and treating diseases that currently 
are not being addressed because of transfer limitations. 
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